26/06/2026 SKYRIZI® received US FDA approval for pediatric psoriatic disease Viridian Therapeutics announced US FDA approval and commercial launch of Lumvoa™ for Thyroid Eye Disease SKYRIZI® received US FDA approval for pediatric psoriatic disease (Ref) AbbVie announced that the US FDA had approved SKYRIZI® (risankizumab-rzaa; IL-23 inhibitor) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic ther

23/06/2026 Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia Sanofi’s tolebrutinib approved in the EU for secondary progressive multiple sclerosis without relapses Abbive announced EC approval of risankizumab for the treatment of pediatric patients with oderate to severe plaque psoriasis Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia (Ref) Sanofi announced that the Ministry of Health, Labour and Welfare in Japan had granted marketing and

18/03/2026 J&J announced FDA approval for icotrokinra for adult and pediatric patients with moderate to severe plaque psoriasis J&J announced FDA approval for icotrokinra for adult and pediatric patients with moderate to severe plaque psoriasis ( Ref ) Johnson & Johnson announced that the US FDA had approved ICOTYDE™ (icotrokinra; IL-23 receptor antagonist) for the treatment of adults and pediatric patients aged 12 years and older who weighed at least 40 kg with moderate to s